Dr. Thomas Schall
you reported our months Steve. quarter been since us we scant good Thank results. quarter conference two a for our everyone exactly afternoon fourth call. on XXXX listening. to Thank to on you first you, And It’s joining
continued So, significant even today across programs. my have our brief. make to I we time, keep progress But, will remarks in that
of is our well trials we in how orphan quite focal dermatological upon intend FSGS, in is Specifically, the our growing X a avacopan in clinical other pivotal CCXI enrollment in other Accordingly, to trial our approved also a we therapies of patient vasculitis. well. today, and complement enjoying disease launch or CX Also, as franchise. in it hidradenitis where avacopan trial, of trials in communities the is the clinical of and cascade FDA is I’ll orphan our where expands suppurativa CCRX our are or one advance CCXXXX push. of pace performing a inhibiting subpopulations of drug how extremely highly candidates segmental nearing completion our glomerulopathy two for avacopan with and differentiated, unlike increasing in Separately, the an settings disease candidates Avacopan major second with the we diseases to highly approach HS innovative as next [ph] planning drug which of the and quite global unlike primary touch or continue ANCA-associated the to glomerulosclerosis to is second space. continues complement Company patient avacopan treatment inhibitor intervention renal -- Phase trial into ADVOCATE to asset no precise make CXG, awareness
treatment ANCA-associated for Let me start with avacopan of the vasculitis.
X ADVOCATE pivotal trial superbly. Our progressing is Phase
enrolled patients number are three, in is weeks of XXX XXX and slides. XX the enrolled now those slide completed shown of The treatment needed, enrollment. enrollment, who nearly are the XX% nearing have of now out you we today, total we first full for patients Indeed their patients following approached as our exact
and online, anti-neutrophil of vasculitis benefit, active current improving major and durable limitations or trial avacopan the is of also the which those blocks now will of unique medical function CXaR, the to or simulated an capsule. CXaRX while disease the and the you of does in care. ADVOCATE depicts ANCA-vasculitis, are refer avacopan clinical the is four, slide of immune and causing which destructive, Through of of Why effect its the CXa highly the how which accordingly alternatively rest targets tissue looking how as avacopan defense. up who is cytoplasmic complement CDXX the precise maintenance will avacopan’s also even references. in And slides neutrophils, following For intact avacopan administered selectively the and one for those possible? in showing complements auto-antibody-associated literature, activation rest of I preserving of standards called so some to the CXa addition mechanism of you test this of action, In system receptor, sometimes preserving the orally
pivotal short, under by ADVOCATE leaders for Importantly, precise it that, X mechanism CXLX ANCA-vasculitis. avacopan clinical previously At better treated, Phase activates Phase trial leads month’s same entirely protective effects we underlying of meetings Foundation, ADVOCATE targets last X. CXa the seen success pathway, Phase X on precision untouched leave is X it of our mode NKF, avacopan draws endpoints, Phase ANCA-vasculitis. and and medicine, that precise outcomes. the beneficial The trial In Phase previously actively patient the measures with our with proceeding action marked and it clinical so this clinical same National designs the we CXa receptor. data doctrine, as in the population to designing ADVOCATE X when the to discussed pivotal actions in the a benefits Kidney trial is occur second The leads avacopan’s of way, and modeled the optimism this the trial have in responsive is that overwhelmingly those
chronic reducing in the and toxicities disease markedly quality of that capsule. with all also total been including marked that and to-date And have rapid devastating this data with of reducing significantly of associated while doses care. of provides in steroids noxious a trials high the life, shows profiles the safety previous the this orally standards burden Our to-date of importantly, administered convenient, control previous excellent in avacopan enhanced of avacopan by treatment standard-of-care ANCA-vasculitis patient
Just on to reflect point. that
of standard-of-care complied late year completion are as such vasculitis. suggests its especially to steroids data form high simply make This is standard-of-care solution so of and have for the the too safer basis to need an of data X the of sometime benefits far, chronic the is trial of This be through the be those of authorization look U.S. obsolete vasculitis may avacopan action. second prednisone come, the with in good As refers front has expect that going too NDA now the the for inadequate disease. ANCA therapy a in diseases a drug you traditional clinical XX% mechanism this The source It In just in Phase is know, standard application gratifying early we conditional that process, ANCA-vasculitis the There the trial results is the application, It treatment next devastating also clinical kidney avacopan orally of and for of regimen. ANCA-vasculitis. on is way nearly you submitted marketing new, review to in we EMA meantime, randomized, ADVOCATE rare, may pivotal CXG FDA ANCA-associated We infected we forward or sometime patients X vasculitis burden far of Phase half no clearly may at application patients, of molecule. a disease regimens small and present. such itself report CX avacopan mainly know, have such which new such based from application CXG and convenience time to for regimen indication final that malady our of has its study avacopan severe an of to year. long current now standard-of-care aim is as differentiated successful, CMA expect terrible that our disease as total glomerulopathy. news and effects unprecedented approved exists. We in in clinical been XXXX. a the its to a for first FDA on forward. in who the the enrolled. or believe many normal opinion next application and clinical We trial and Avacopan of represent will the a very as and methylprednisolone And controlled for ANCA-associated much this today in of the of true doses though is from our is the taken avacopan. for
good So, progress. the very making trial is
control patients for months six-month a is cohort As seen comparing group can and then patients the and XX will index avacopan. the endpoints CX study trial Other in be six will assessed who cross percentage on the avacopan of of placebo after the of receive will histological a five, six kidney well. over slide XX endpoint be change primary as The primary months standard endpoint placebo function is patients to treatment. the with
avacopan the for As mentioned, to progression tissue By is effective CXG the transplants also failure the that with CX disease. sometimes of is activation excellent downstream treated inflammation presence the as in And the kidney only cause CX people kidney dialysis complement deposition but in experience transplants, by kidney in who no and is and in which the protein CXa certainly the all the people CXa destructive function. making blocking treatment. you kidney of and typically which proteins destruction kidney and of cells approved is glomeruli disrupts And its this the life-threatening, from not Half could glomerulopathy. the failure. deposits, CXG for disease of are kidney transplant. Complement by CX target there and receptor, an inhibit ultimately system and CXG frequently proteins of with young would characterized fail even often often with halt ultimate strikes name, a the avacopan. and deposition organ expect kidney CXG those disorder the
comprises second unique orphan Now, least armamentarium diseases. CCXXXX. turning discussion, innovative indeed CCXXXX of drug our the second at part candidate, new renal for to today’s for of our therapies
of six. treatment known for as In the slide focal FSGS. Our the glomerulosclerosis is disorder as chronic FSGS shown March, kidney journal is CCXXXX debilitating disorder approved in or segmental another in with no option, indication published examining CCRX known systems. we ONE, in the which treatment of of in chemokine the results target the CCXXXX our model is PLOS inhibiting studies, efficacy vivo of in receptor FSGS as peer-reviewed
in published show two There density. protection improved and models renal blocking that sustained with histological in well marked as meeting presentation further European Era-Edta increased - reductions approach These in large the these rapid of podocyte data our well-established Copenhagen as a data Dialysis this proteinuria Association at month. be later and support CCRX including provides FSGS. Renal will in Our FSGS changes of Association Transplant findings European upcoming or
CCXXXX, conducting with nephrotic are another primary with our with We FSGS studies clinical FSGS, inhibitor one primary patients in in CCRX patients. sub-nephrotic syndrome two and
these the we have for especially proteinuria. in proteinuria that indicated experience the constitute good a Phase FSGS diabetes, process significant occurs that degree registration. of one these nephrotic its patients are renal a well lowering a clinical a disease met syndrome nephropathy We Type of patients of large in kidney endpoint in in studies. X primary And one-year, may significant importantly, year disease setting. FDA endpoint CCXXXX of has durable, actively for with itself that patients, currently a is that reduction of recruiting X with the in to FSGS chronic consequence long, as diabetic CCXXXX recall trial
dermatological Finally, orphan into with I our touch expansion would upon diseases. like exciting avacopan to
in disease on working up a lives drug, pipeline development initiate we to avacopan area, avacopan description hidradenitis or clinical our are HS. to a new of suppurativa As as its in plans a
unmet As slide seven, represents significant HS very, you can very see a on need. clinical
great appears potential great for room improvement And sales a only of disease a at the to and therapy consensus antibody important is $X the in communities are received dermatological have an path CCXI in is physiology therapy. fascinated incumbent HS. neutrophil-mediated Nevertheless CXa community. There The of is driving in HS HS. have an They from disease. disease. where approaching to be as interest rheumatological in the are demand billion investigational this deal We HS disruptive in of incumbent neutrophils approved role plays we a that clinical in this the that seems therapeutic
will HS. in Make the remedy and era ChemoCentryx Our indication. a in is plan our in move a will preview be could avacopan that that chronic this effective that valuable update belief pipeline On mark asset we near-term, swiftly into be in scale you HS no coming area topic, the important ultimately era but be could more extended of development as avacopan I will new and very details In diseases with this another avacopan in out dermatological need an second important of mistake, this that orphan is new of and that diseases. and avacopan the by of platform. may orphan will development certainly move this dermatological of we just dermatological discovery our anchored addition a
and inhibitor orally an Specifically, known or of is inflammatory study skin need, and in in area a GPP psoriasis say for could unique potential as extremely small GPP. administered high key of value disorder rare the large therapy chemokine play pustular molecule the and CCRX receptor creation. clinical orphan disease role unmet a
next those pustular disease properties discuss of exciting meeting days at a I presented of that the at week takes Austin poster will presented International in the Investigative in calls. asset be in Institute models Immunologists place generalized molecules new will this more poster American CCRX for detail recently future fact, the Dermatology In Orlando two inhibiting meeting on in we another psoriasis. and ago including in
sheet. As review and you remind we Susan? funds and avacopan Susan balance tradition to to signings will CCXI. I our We the I example Capital sufficient potential our data ADVOCATE at EU. turn that for Phase a pivotal here to very and have registration X top-line believe in from we into long-standing financials, trial U.S. advance the a over have proud efficiency to being call healthy
